Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 7/2017

01-07-2017 | Original Contributions

Bariatric Roux-En-Y Gastric Bypass Surgery: Adipocyte Proteins Involved in Increased Bone Remodeling in Humans

Authors: Maria Fernanda G Biagioni, Adriana L Mendes, Célia Regina Nogueira, Celso V Leite, Loraine Gollino, Gláucia MFS Mazeto

Published in: Obesity Surgery | Issue 7/2017

Login to get access

Abstract

Purpose

Bariatric surgery has been associated with bone remodeling changes. The action of adipokines on the expression of receptor activator of nuclear factor kappa β ligand (RANKL) and osteoprotegerin (OPG) and on an increase in sclerostin could be related to these changes.

Materials and Methods

This study aimed to assess the repercussions of weight loss, fat mass (FM), and fat-free mass (FFM) loss and biochemical and hormonal changes on bone remodeling markers after Roux-en-Y gastric bypass (RYGB). Anthropometric data, parathyroid hormone (PTH), bone-specific alkaline phosphatase (BSAP), collagen type 1 C-telopeptide (CTX), 25-hydroxy vitamin D (25-OH-VitD), leptin, adiponectin, RANKL, OPG, and sclerostin of 30 menstruating women were measured preoperatively (Pre), and 3, 12, and 24 months (m) after RYGB.

Results

Leptin (34.4 (14.7; 51.9) vs. 22.5 (1.9; 52.7) ng/mL) and OPG (3.6 (1.1; 11.5) vs. 3.4 (1.5; 6) pmol/L) decreased, and adiponectin (7.4 (1.7; 18.4) vs. 13.8 (3.0; 34.6) μg/mL), CTX (0.2 (0.1; 2.2) vs. 0.6 (0.4; 6.0) ng/mL), RANKL (0.1 (0.0; 0.5) vs. 0.3 (0.0; 2.0) pmol/L), and sclerostin (21.7 (3.2; 75.1) vs. 34.8 (6.4; 80.5) pmol/L) increased after 3 m. BSAP increased after 12 m (10.1 (5.4; 18.9) vs. 13.9 (6.9; 30.2) μg/mL) (p < 0.005). CTX correlated positively with adiponectin at 24 m and inversely with leptin Pre; OPG at 3 m; weight, FM, FFM, and leptin at 24 m. RANKL correlated directly with weight at 3 m. Sclerostin correlated inversely with weight Pre and FM at 3 m. BSAP correlated negatively with 25-OH-VitD at 12 m, and positively with PTH at 24 m.

Conclusions

RYGB induced weight loss, and biochemical, hormonal, and body composition changes are associated with higher bone remodeling.
Literature
1.
2.
Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract. 2008;14(Suppl 1):1–83.CrossRefPubMed
3.
Ricci C, Gaeta M, Rausa E, et al. Early impact f bariatric surgery on type II diabetes, hipertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6.587 patients. Obes Surg. 2014;24:522–8.CrossRefPubMed
4.
5.
Stemmer K, Bielohuby M, Grayson BE, et al. Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats. Endocrinology. 2013;154:2015–24.CrossRefPubMedPubMedCentral
6.
Stein EM, Silverberg SJ. Bone loss after bariatric surgery: causes. Consequences and Management Lancet Diabetes Endocrinol. 2014;2(2):165–74.CrossRefPubMed
7.
Yu EW, Bouxsein ML, Putman MS, et al. Two-year changes in bone density after Roux-en-Y gastric bypass surgery. J Clin Endocrinol Metab. 2015;100(4):1452–9.CrossRefPubMedPubMedCentral
8.
Liu C, Wu D, Zhang J, et al. Changes in bone metabolism in morbidly obese patients after bariatric surgery: a meta-analysis. Obes Surg. 2016;26(1):91–7.CrossRefPubMed
9.
10.
Karefylakis C, Näslund I, Edholm D, et al. Vitamin D status 10 years after primary gastric bypass: gravely high prevalence of hypovitaminosis D and raised PTH levels. Obes Surg. 2014;24(3):343–8.CrossRefPubMed
11.
Hage MP, El-Hajj FG. Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass. Osteoporosis Int. 2014;25:423–39.CrossRef
12.
Butte NF, Brandt ML, Wong WW, et al. Energetic adaptations persist after bariatric surgery in severely obese adolescents. Obesity (Silver Spring). 2015;23(3):591–601.CrossRefPubMedCentral
13.
Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblastos through the MAPK signalling pathway. J Bone Miner Res. 2006;21:1648–56.CrossRefPubMed
14.
Nakamichi Y, Udagawa N, Kobayashi Y, et al. Osteoprotegerin reduces the serum level of receptor activator of NF-ΚB ligand derived from osteoblasts. J Immunol. 2007;178:192–200.CrossRefPubMed
15.
Elissondo N, Rosso LG, Maidana P, et al. Adiponectina: una adipocitoquina con múltiples funciones protectoras. Acta Bioquím Clín Latinoam. 2008;42(1):17–33.
16.
17.
18.
19.
Grethen E, Hill KM, Jones R, et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab. 2012;97(5):1655–62.CrossRefPubMedPubMedCentral
20.
Muschitz C, Kocijan R, Marterer C, et al. Sclerostin levels and changes in bone metabolism after bariatric surgery. J Clin Endocrinol Metab. 2015;100(3):891–901.CrossRefPubMed
21.
Wijenayaka AR, Kogawa M, Lim HP, et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:e25900.CrossRefPubMedPubMedCentral
22.
Atkins GJ, Rowe PS, Lim HP, et al. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011;26:1425–36.CrossRefPubMedPubMedCentral
23.
24.
Lewiecki EM. Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discov Med. 2011;12(65):263–73.PubMed
25.
Dovjak P, Dorfer S, Föger-Samwald U, et al. Serum levels of sclerostin and dickkopf-1: effects of age, gender and fracture status. Gerontology. 2014;60:493–501.CrossRefPubMed
26.
Eriksen EF. Commentary on sclerostin deficiency is linked to altered bone composition. J Bone Miner Res. 2014;29(10):2141–3.CrossRefPubMed
27.
Fleischer J, Stein EM, Bessler M, et al. The decline in hip bone density after gastric bypass surgery is associated with extent of weight loss. J Clin Endocrinol Metab. 2008;93(10):3735–40.CrossRefPubMedPubMedCentral
28.
Gannagé-Yared MH, Yaghi C, Habre B, et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol. 2008;158(3):353–9.CrossRefPubMed
29.
Wroblewski E, Swidnicka-Siergiejko A, Hady HR, et al. Variation in blood levels of hormones in obese patients following weight reduction induced by endoscopic and surgical bariatric therapies. Cytokine. 2016;77:56–62.CrossRefPubMed
30.
Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Endocr Pract. 2013;19(2):337–72.CrossRefPubMedPubMedCentral
31.
Viégas M, Vasconcelos RS, Neves AP, et al. Bariatric surgery and bone metabolism: a systematic review. Arq Bras Endocrinol Metabol. 2010;54(2):158–63.CrossRefPubMed
32.
Vasconcelos RS, Viégas M, Marques TF, et al. Factors associated with secondary hyperparathyroidism in premenopausal women undergoing Roux-en-Y gastric bypass for the treatment of obesity. Arq Bras Endocrinol Metabol. 2010;54(2):233–8.CrossRefPubMed
33.
34.
Carrasco F, Basfi-fer K, Rpjas P, et al. Changes in bone mineral density after sleeve gastrectomy or gastric bypass: relationships with variations in vitamin D, ghrelin, and adiponectin levels. Obes Surg. 2014;24:877–84.CrossRefPubMed
35.
Register TC, Divers J, Bowden DW, et al. Relationships between serum adiponectin and bone density, adiposity and calcified atherosclerotic plaque in the African American-Diabetes Heart Study. J Clin Endocrinol Metab. 2013 May;98(5):1916–22.CrossRefPubMedPubMedCentral
36.
Balsa JA, Lafuente C, Gómez-Martín JM, et al. The role of serum osteoprotegerin and receptor–activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery. J Bone Miner Metab. 2015;1-7
37.
Elias E, Casselbrant A, Werling M, et al. Bone mineral density and expression of vitamin D receptor-dependent calcium uptake mechanisms in the proximal small intestine after bariatric surgery. Br J Surg. 2014;101(12):1566–75. doi:10.​1002/​bjs.​9626.CrossRefPubMed
38.
Bruno C, Fulford AD, Potts JR, et al. Serum markers of bone turnover are increased at six and 18 months after Roux-en-Y bariatric surgery: correlation with the reduction in leptin. J Clin Endocrinol Metab. 2010;95(1):159–66. doi:10.​1210/​jc.​2009-0265.CrossRefPubMed
39.
Biagioni MFG, Mendes AL, Nogueira CR, et al. Weight-reducing gastroplasty with Roux-en-Y gastric bypass: impact on vitamin D status and bone remodeling markers. Metab Syndr Relat Disord. 2014;12(1):11–5.CrossRefPubMed
40.
Oshima K, Nampei A, Matsuda M, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun. 2005;331(2):520–6.CrossRefPubMed
41.
Lenchik L, Register TC, Hsu FC, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003;33(4):646–51.CrossRefPubMed
42.
Aguirre L, Napoli N, Waters D, et al. Increasing adiposity is associated with higher adipokine levels and lower bone mineral density in obese older adults. J Clin Endocrinol Metab. 2014;99(9):3290–7.CrossRefPubMedPubMedCentral
43.
Naot D, Cornish J. Cytokines and hormones that contribute to the positive association between fat and bone. Front Endocrinol. 2014;5:70.CrossRef
44.
Carrasco F, Ruz M, Rojas P, et al. Changes in bone mineral density, body composition and adiponectin levels in morbidly obese patients after bariatric surgery. Obes Surg. 2009;19(1):41–6.CrossRefPubMed
45.
Bruno C, Fulford AD, Potts JR, et al. Serum markers of bone turnover are increased at six and 18 months after Roux-en-Y bariatric surgery: correlation with the reduction in leptin. J Clin Endocrinol Metab. 2010;95:159–66.CrossRefPubMed
46.
Prado WL, Piano A, Lazaretti-Castro M, et al. Relationship between bone mineral density, leptin and insulin concentration in Brazilian obese adolescents. J Bone Miner Metab. 2009;27:613–9.CrossRefPubMed
47.
Thomas T, Burguera B. Is leptin the link between fat and bone mass? J Bone Miner Res. 2002;17:1563–9.CrossRefPubMed
48.
Walicka M, Czerwińska E, Tałałaj M, et al. Influence of weight reduction on leptin concentration and bone mineral density in patients with morbid obesity before and 6 months after bariatric surgery. Endokrynologia Polska. 2009;60(2):97–102.PubMed
49.
Mohiti-Ardekani J, Soleymani-Salehabadi H, et al. Relationships between serum adipocyte hormones (adiponectin, leptin, resistin), bone mineral density and bone metabolic markers in osteoporosis patients. J Bone Miner Metab. 2014;32(4):400–4.CrossRefPubMed
50.
51.
Zhang R, Oyajobi BO, Harris SE, et al. Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone. 2013;52(1):145–56.CrossRefPubMed
52.
Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.CrossRefPubMed
53.
Wang Y, Lam KS, Xu JY, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem. 2005;280:18341–7.CrossRefPubMed
54.
Schoenau E. Bone mass increase in puberty: what makes it happen? Horm Res Paediatr. 2006;65(2):2–10.CrossRef
55.
56.
Van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007;22(1):19–28.CrossRefPubMed
57.
Schwartz AV, Johnson KC, Kahn SE, et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the look AHEAD randomized trial. J Bone Miner Res. 2012;27(3):619–27.CrossRefPubMedPubMedCentral
58.
Bellido T. Summary—osteocyte control of bone formation via Sost/sclerostin. J Musculoskelet Neuronal Interact. 2006;6(4):360–3.
59.
Granado-Lorencio F, Simal-Antón A, Salazar-Mosteiro J, et al. Time-course changes in bone turnover markers and fat-soluble vitamins after obesity surgery. Obes Surg. 2010;20:1524–9.CrossRefPubMed
60.
Villareal RA, Sadler C, Napoli N, et al. Weight loss in obese older adults increases serum sclerostin and impairs hip geometry but both are prevented by exercise training. Bone Miner Res. 2012;27(5):1215–21.CrossRef
61.
Muschitz C, Kocijan R, Haschka J, et al. The impact of vitamin D, calcium, protein supplementation, and physical exercise on bone metabolism after bariatric surgery: the BABS study. J Bone Miner Res. 2016;31(3):672–82.CrossRefPubMed
62.
Deitel M, Greenstein R. Editorial: recommendations for reporting weight loss. Obes Surg. 2003;13:159–60.CrossRefPubMed
Metadata
Title
Bariatric Roux-En-Y Gastric Bypass Surgery: Adipocyte Proteins Involved in Increased Bone Remodeling in Humans
Authors
Maria Fernanda G Biagioni
Adriana L Mendes
Célia Regina Nogueira
Celso V Leite
Loraine Gollino
Gláucia MFS Mazeto
Publication date
01-07-2017
Publisher
Springer US
Published in
Obesity Surgery / Issue 7/2017
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-017-2546-4

Other articles of this Issue 7/2017

Obesity Surgery 7/2017 Go to the issue

Original Contributions

Obesity, Hypersomnolence, and Quality of Sleep: the Impact of Bariatric Surgery

Original Contributions

Factors Associated with Increased Experience of Postoperative Pain after Laparoscopic Gastric Bypass Surgery

Original Contributions

Evolution of Liver Steatosis Quantified by MR Imaging and MR Spectroscopy, in Morbidly Obese Patients Undergoing Sleeve Gastrectomy: Short-Term Outcomes

Original Contributions

Does Post-operative Psychotherapy Contribute to Improved Comorbidities in Bariatric Patients with Borderline Personality Disorder Traits and Bulimia Tendencies? A Prospective Study

Original Contributions

Preserved Fat-Free Mass after Gastric Bypass and Duodenal Switch

New Concept

Surgical Management of Obesity Among People with Schizophrenia and Bipolar Disorder: a Systematic Review of Outcomes and Recommendations for Future Research